

- **Investment Rational**

Biond Biologics is developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform for cancer treatment. While the immuno-oncology field has witnessed major advancements, there is still an unmet need for new, more effective therapies. Biond has successfully partnered with Sanofi for BND-22, a novel immune checkpoint inhibitor targeting ILT2 and initiated Phase 1/2 trial for cancer patients with solid tumors.
- **Business Strategy**

BND-22 was partnered with Sanofi for \$125 million upfront and up to \$1 billion in various milestones. Biond's Immuno-Oncology pipeline includes two pre-clinical programs that are expected to reach the clinic in 2024. Biond is developing INspire, a delivery platform for biologics, generating a long-term pipeline for intracellular targets which can yield multiple collaborations and licensing deals with global pharma.
- **Core Technology**

Biond's pipeline is based on the research of less-charted waters in the fields of immune-checkpoints and immune-evasion, discovered through in-house research utilizing real-world patient and tumor samples. INspire, is an efficient solution for targeting intracellular proteins that thus far were inaccessible for biologics.
- **Product Profile/Pipeline**

Biond's pipeline:

 - BND-22, licensed to Sanofi with major upcoming milestones.
 - BND-35, a monoclonal antibody targeting Immunoglobulin-like transcript 3 (ILT3); and
 - BND-67, a nanobody-based agent that targets a novel mechanism of CD28 shedding. Both are in preclinical stage and available for partnering.
 - INspire platform: in-vitro and in-vivo delivery of biologics already demonstrated, and first products are in development.
- **What's Next?**

Biond is continuing the phase I dose escalation clinical trial of BND-22 as monotherapy and in combination with approved therapies and is advancing the development of the pre-clinical projects towards clinical stages. Biond has secured funds to advance the pre-clinical pipeline and the first products using the INspire platform for the treatment of cancer patients.